What does the evidence say about Whey Protein Satiety Randomized Trial?

Updated June 2026

Quick Answer

Whey Protein Satiety Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: 2016 2020 2019 2025 2023 2024 2019 2019 2019 2024 2019 Accelerated global population aging has made the progressive decline in skeletal muscle mass and associated physical functional deterioration among older adults a major public health concern.

Key Takeaways

  • 012016 2020 2019 2025 2023 2024 2019 2019 2019 2024 2019 Accelerated global population aging has made the progressive decline in skeletal muscle mass and associated physical functional deterioration among older adults a major public health concern. [Huijing Bai (2026)]
  • 02For instance, a UK study found that dynapenia (a key component of sarcopenia) was associated with markedly increased healthcare and social care costs, with annual additional medical expenses attributable to muscle weakness reaching £2.5 billion (Bruyère et al. ). [Huijing Bai (2026)]
  • 03This study is expected to provide scientific evidence for optimizing protein supplementation strategies in this population. [Huijing Bai (2026)]
  • 04Of particular concern is that sarcopenia substantially elevates healthcare expenditures and overall medical burden (Darvishi et al. ). [Huijing Bai (2026)]
The current Migaku evidence database contains 2 reusable source documents for Whey Protein Satiety Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 2016 2020 2019 2025 2023 2024 2019 2019 2019 2024 2019 Accelerated global population aging has made the progressive decline in skeletal muscle mass and associated physical functional deterioration among older adults a major public health concern. [Huijing Bai (2026); evidence level 2] - For instance, a UK study found that dynapenia (a key component of sarcopenia) was associated with markedly increased healthcare and social care costs, with annual additional medical expenses attributable to muscle weakness reaching £2.5 billion (Bruyère et al. ). [Huijing Bai (2026); evidence level 2] - This study is expected to provide scientific evidence for optimizing protein supplementation strategies in this population. [Huijing Bai (2026); evidence level 2] - Of particular concern is that sarcopenia substantially elevates healthcare expenditures and overall medical burden (Darvishi et al. ). [Huijing Bai (2026); evidence level 2] - Their increasing prevalence has been strongly associated with the presence of multiple cardiometabolic risk factors—including elevated systolic blood pressure, high low-density lipoprotein cholesterol (LDL-c), elevated body mass index (BMI), and elevated fasting glucose—often exacerbated by unhealthy lifestyle behaviors such as physical inactivity and poor dietary habits []. [Tavares Isabela Ribeiro Grangeira (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. The Impact of Oral Whey Protein and Yeast Protein Supplementation for 6 Months on Skeletal Muscle Mass, Strength, and Function in the Elderly: A Randomized, Controlled, Parallel Study
  2. Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review